References
- Grothey A, Van Cutsem E, Sobrero A et al.; CORRECT Study Group. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, Phase 3 trial. Lancet 381(9863), 303–312 (2013).
- Van Cutsem EJD, Grothey A, Sobrero A et al. Phase 3 CORRECT trial of regorafenib in metastatic colorectal cancer (MCRC): overall survival update. Ann. Oncol. LBA18 (2012).
- Demetri GD, Reichardt P, Kang YK et al.; GRID Study Investigators. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, Phase 3 trial. Lancet 381(9863), 295–302 (2013).
- Douillard JY, Cunningham D, Roth AD et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355(9209), 1041–1047 (2000).
- Seymour MT, Maughan TS, Ledermann JA et al.; FOCUS Trial Investigators; National Cancer Research Institute Colorectal Clinical Studies Group. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet 370(9582), 143–152 (2007).
- de Gramont A, Figer A, Seymour M et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J. Clin. Oncol. 18, 2938–2947 (2000).
- Tournigand C, André T, Achille E et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J. Clin. Oncol. 22(2), 229–237 (2004).
- Van Cutsem E, Hoff PM, Harper P et al. Oral capecitabine vs. intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised Phase III trials. Brit. J. Cancer 90, 1190–1197 (2004).
- Koopman M, Antonini NF, Douma J et al. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a Phase III randomised controlled trial. Lancet 370(9582), 135–142 (2007).
- Grothey A, Sargent D, Goldberg RM, Schmoll HJ. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J. Clin. Oncol. 22(7), 1209–1214 (2004).
- Rougier P, Van Cutsem E, Bajetta E et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 352(9138), 1407–1412 (1998).
- Van Cutsem E, Tabernero J, Lakomy R et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a Phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J. Clin. Oncol. 30(28), 3499–3506 (2012).
- Saltz LB, Clarke S, Díaz-Rubio E et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized Phase III study. J. Clin. Oncol. 26(12), 2013–2019 (2008).
- Karapetis CS, Khambata-Ford S, Jonker DJ et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med. 359(17), 1757–1765 (2008).
- Peeters M, Price TJ, Cervantes A et al. Randomized Phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J. Clin. Oncol. 28(31), 4706–4713 (2010).
- Folkman J. Angiogenesis. Annu. Rev. Med. 57, 1–18 (2006).
- Folkman J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285(21), 1182–1186 (1971).
- Wilhelm SM, Dumas J, Adnane L et al. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int. J. Cancer 129(1), 245–255 (2011).
- Wilhelm SM, Carter C, Tang L et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 64(19), 7099–7109 (2004).
- Mross K, Frost A, Steinbild S et al. A Phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors. Clin. Cancer Res. 18(9), 2658–2667 (2012).
- Hedbom S, Steinbild S, Frost A et al. Phase I study of BAY 73-4506, amultikinase inhibitor, administered for 21 days on/7 days off in patients withadvanced solid tumors. J. Clin. Oncol. 25(18S), Abstract 3593 (2007).
- Strumberg D, Scheulen ME, Schultheis B et al. Regorafenib (BAY 73-4506) in advanced colorectal cancer: a Phase I study. Br. J. Cancer 106(11), 1722–1727 (2012).
- Zopf D, Heinig R, Thierauch KH et al. Regorafenib (BAY 73-4506): preclinical pharmacology and clinical identification and quantification of its major metabolites. Presented at: American Association for Cancer Research 101st Annual Meeting. Washington, DC, USA, 17–21 April 2010.
- Shimizu T, Tolcher AW, Patnaik A et al. Phase I dose-escalation study ofcontinuously administered regorafenib(BAY 73-4506), an inhibitor ofoncogenic and angiogenic kinases, inpatients withadvanced solid tumors. J. Clin. Oncol. 28(15S), Abstract 3035 (2010).
- Eisen T, Joensuu H, Nathan P et al. Phase II trial of the oral multikinase inhibitor regorafenib (BAY 73-4506) as first-line therapy in patients with metastatic or unresectable renal cell carcinoma (RCC). Eur. J. Cancer 47, 7141 (2011).
- Eisen T, Joensuu H, Nathan PD et al. Regorafenib for patients with previously untreated metastatic or unresectable Renal cell carcinoma: a single-group Phase 2 trial. Lancet Oncol. 13(10), 1055–1062 (2012).
- George S, Wang Q, Heinrich MC et al. Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter Phase II trial. J. Clin. Oncol. 30(19), 2401–2407 (2012).
- Schultheis B, Folprecht G, Kuhlmann J et al. Phase I study of regorafenib sequentially administered with either FOLFOX or FOLFIRI in patients with first-/second line colorectal cancer. J. Clin. Oncol. 29, Abstract 3585 (2011).
- Reichardt P, Casali PG, Kang YK et al. Clinical benefit with regorafenib across subgroups and post-progression in patients with advanced gastrointestinal stromal tumor after progression on imatinib and sunitinib: Phase 3 GRID trial update, 2012 ESMO Congress. Abstract 14780 (2012).
- Masi G, Loupakis F, Salvatore L et al. A randomised Phase III study evaluating the continuation of bevacizumab beyond progression in metastatic colorectal cancer patients who received bevacizumab as part of first-line treatment. Results of the BEBYP trial by the Gruppo Oncologico Nord Ovest. ESMO Congress. Abstract LBA17 (2012).
- Kies MS, Holsinger FC, Lee JJ et al. Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: results from a Phase II prospective trial. J. Clin. Oncol. 28(1), 8–14 (2010).
- Jeffers M, Quinn D, Joensuu H et al. Identification of plasma biomarkers for the multikinase inhibitor regorafenib (BAY 73-4506) in patients (pts) with renal cell cancer (RCC). Ann. Oncol. 21, 1238 (2010).
- O’Connor JP, Jackson A, Parker GJ et al. Dynamic contrast-enhanced MRI in clinical trials of antivascular therapies. Nat. Rev. Clin. Oncol. 9, 167–177 (2012).
- Van Den Abbeele AD, Tanaka Y, Locascio T et al. Assessment of regorafenib activity with FDG-PET/CT in a multicenter Phase II study in patients (pts) with advanced gastrointestinal stromal tumor (GIST) following failure of standard therapy (Rx). J. Clin. Oncol. 29, Abstract 10050 (2011).
Websites
- Highlights of Prescribing Information. www.accessdata.fda.gov/drugsatfda_docs/label/2012/203085lbl.pdf
- ClinicalTrials.gov. http://clinicaltrials.gov/